Skip to main content

Table 2 Subject demographic information and data

From: Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection

Demographics Neuropathology Imaging
Case Age Sex Timea Dementiab mCsc d ADe CERADf Braakg Amyloid phaseh Diagnosesi SUVRj PETmajk
1 73 F 360 Yes 0.0 n.d. Normal - II 1 Inf TDPl 1.13 Normal
2 84 M 17 Yes 0.0 0.3 Normal - I 0 Normal 1.18 Normal
3 83 M 568 No 0.0 n.d. Normal - IV 1 LBD 1.17 Normal
4 91 M 130 Yes 0.0 0.9 Normal - 0 0 PSP VAD 1.34 Normal
5 63 M 433 No 0.0 n.d. Low - II 1 PSP 1.42 Normal
6 76 F 145 Yes 0.0 n.d. Normal - II 1 LBD VAD 1.22 Normal
7 70 M 16 No 0.0 n.d. Normal - 0 0 Normal 1.44 Normal
8 67 M 32 No 0.0 n.d. Normal - I 0 Normal 1.37 Normal
9 80 M 131 Yes 0.0 n.d. NA - III 0 TPD 1.26 Normal
10 61 F 34 No 0.0 n.d. Normal - 0 1 Normal 1.67 Normal
11 65 F 393 No 0.0 n.d. Normal - III 1 AC 1.21 Normal
12 60 M 374 No 0.0 n.d. Low - III 1 VAD 1.34 Normal
13 74 M 170 Yes 0.1 8.1 Normal - 0 2 VAD 1.12 Normal
14 66 M 155 No 0.1 n.d. Normal - 0 0 AC 1.3 Normal
15 76 F 10 Yes 0.1 0.2 Normal - I 2 Normal 1.56 Normal
16 63 M 12 No 0.1 n.d. Normal - 0 0 Normal 1.6 Normal
17 73 F 105 Yes 0.5 0.4 Normal - V 1 TPD 1.34 Normal
18 90 F 115 Yes 0.0 n.d. Low S III 1 Inf AS 1.4 Normal
19 89 F 78 No 0.3 n.d. Int S IV 2 CAA AD 1.25 Normal
20 82 F 24 Yes 0.4 0 Low S III 1 LBD 1.72 Normal
21 92 F 210 Yes 0.7 n.d. Normal S II 4 CAA PD 1.55 Normal
22 84 F 69 Yes 1.1 1 Int S II 2 Inf 1.36 Normal
23 72 M 142 Yes 1.3 n.d. Normal S 0 3 FTD 1.01 Normal
24 87 F 76 Yes 1.4 2 Low S I 3 VAD 1.57 Normal
25 87 F 137 Yes 1.5 n.d. Normal S 0 2 AC AS 1.53 Normal
26 60 M 11 Yes 1.7 n.d. Low S II 4 CAA 1.08 Normal
27 81 M 189 No 1.8 n.d. Normal S I 4 ND 1.6 Normal
28 92 F 212 Yes 2.1 n.d. Int S III 3 TDPl 1.26 Normal
29 87 F 131 Yes 1.4 8.1 Low S IV 5 LBD 1.95 Abnormal
30 96 F 630 Yes 1.9 n.d. High S VI 5 AD 2.15 Abnormal
31 92 F 132 Yes 1.9 n.d. Low S III 4 LBD 2.72 Abnormal
32 89 F 311 Yes 2.0 n.d. Int S III 5 AD CAA VAD 2.33 Abnormal
33 88 F 118 Yes 2.1 n.d. Low S II 4 Inf LBD AS 3.14 Abnormal
34 80 M 2 Yes 2.1 7.6 High S VI 5 AD LBD 2.1 Abnormal
35 94 F 19 Yes 2.1 7.7 Int S III 5 AD 1.95 Abnormal
36 88 F 329 Yes 2.1 n.d. High S V 5 AD 2.84 Abnormal
37 74 F 550 Yes 2.8 n.d. High S VI 5 AD 2.23 Abnormal
38 86 M 19 No 1.4 2.3 Int M III 3 AD 1.45 Normal
39 75 M 64 Yes 1.4 1.4 Int M II 3 Inf LBD 1.23 Normal
40 84 M 349 Yes 1.6 n.d. Int M V 3 AD LBD AS VAD Ath 1.73 Normal
41 93 M 323 No 1.9 n.d. Low M II 3 LBD 1.36 Normal
42 87 M 22 No 2.7 4 Int M IV 4 AD 2.04 Normal
43 86 F 193 Yes 0.3 9.4 Low M III 4 LBD 2.07 Abnormal
44 76 M 84 Yes 1.5 10.3 Low M II 3 LBD 1.87 Abnormal
45 75 M 373 Yes 1.6 n.d. Int M IV 5 AD CAA 1.48 Abnormal
46 82 F 127 Yes 1.7 n.d. Int M IV 4 AD LBD 2.32 Abnormal
47 86 M 395 Yes 1.8 n.d. High M V 5 AD 2.83 Abnormal
48 93 F 500 Yes 1.8 n.d. Int M V 3 AD AS VAD 1.6 Abnormal
49 84 M 45 Yes 1.8 n.d. Low M II 3 VAD 1.85 Abnormal
50 93 F 243 Yes 1.9 n.d. High M VI 5 AD 2.72 Abnormal
51 93 F 755 Yes 2.0 n.d. High M IV 5 AD 2.2 Abnormal
52 80 M 276 Yes 2.0 n.d. High M VI 4 AD 2.33 Abnormal
53 90 M 308 Yes 2.1 n.d. Low M II 4 LBD 2.19 Abnormal
54 78 M 62 Yes 2.1 10.1 High M VI 5 AD LBD 2.86 Abnormal
55 86 F 747 Yes 2.1 n.d. Int M IV 3 AD CAA 1.81 Abnormal
56 73 F 295 No 2.2 n.d. Low M I 3 LBD 1.76 Abnormal
57 87 F 318 Yes 2.2 n.d. Int M III 5 AD AS VAD Ath 2.26 Abnormal
58 88 F 266 Yes 2.2 n.d. Int M III 4 AD LBD 1.91 Abnormal
59 88 F 79 Yes 2.3 17.6 High M VI 5 AD 1.67 Abnormal
60 93 F 396 Yes 2.3 n.d. High M VI 5 AD CAA Inf 3.08 Abnormal
61 85 M 60 No 2.4 14.7 High M VI 5 CAA AD VAD 2.81 Abnormal
62 91 M 30 Yes 2.4 2.9 High M V 4 AD 1.86 Abnormal
63 95 F 15 Yes 2.4 7.5 High M VI 5 AD 1.89 Abnormal
64 79 M 42 No 2.4 n.d. Int M III 4 CAA mCa AD 2.44 Abnormal
65 81 F 184 Yes 2.5 n.d. Int M IV 3 LBD 1.66 Abnormal
66 84 F 193 Yes 2.6 n.d. High M V 5 AD 2.4 Abnormal
67 72 M 268 Yes 2.7 n.d. High M VI 5 AD VAD 2.07 Abnormal
68 63 M 342 Yes 2.8 n.d. High M VI 5 AD AS VAD 1.94 Abnormal
69 89 F 115 Yes 3.0 n.d. High M VI 5 AD CAA LBD AS 2.39 Abnormal
70 83 F 611 Yes 1.8 n.d. Low F I 4 AS CAA VAD TDPl 1.87 Normal
71 84 F 189 No 1.7 n.d. Int F 0 3 CAA Inf VAD AD 2.02 Abnormal
72 82 M 397 Yes 1.9 n.d. High F VI 5 AD CAA VAD 2.41 Abnormal
73 86 F 155 Yes 2.0 n.d. High F V 5 AD 2.43 Abnormal
74 93 F 594 Yes 2.0 n.d. High F IV 5 AD 2.46 Abnormal
75 90 F 538 Yes 2.0 n.d. High F VI 4 AD CAA AS VAD 2.78 Abnormal
76 78 F 180 Yes 2.2 n.d. Normal F 0 4 MSA 2.03 Abnormal
77 93 F 200 Yes 2.2 n.d. High F V 5 AD AS CAA LBD VAD 2.42 Abnormal
78 78 F 125 Yes 2.2 n.d. High F VI 5 AD LBD 2.12 Abnormal
79 72 M 1 Yes 2.4 11.4 High F VI 5 AD 2.37 Abnormal
80 76 F 27 Yes 2.4 n.d. High F VI 5 AD CAA 1.83 Abnormal
81 77 F 11 Yes 2.4 8.9 High F VI 4 AD 1.59 Abnormal
82 91 F 55 Yes 2.4 11.2 High F VI 4 AD CAA 2.2 Abnormal
83 81 M 204 Yes 2.4 n.d. High F VI 4 AD CAA LBD 2.41 Abnormal
84 82 M 15 Yes 2.5 6.9 High F VI 4 AD CAA 2.23 Abnormal
85 83 M 34 Yes 2.5 8.5 High F VI 5 AD 2.6 Abnormal
86 90 F 51 Yes 2.5 12.2 High F VI 4 AD 2.35 Abnormal
87 73 F 27 Yes 2.5 9.6 High F VI 5 AD 2.23 Abnormal
88 87 M 1 Yes 2.5 7.8 High F IV 4 AD CAA 2.1 Abnormal
89 89 F 768 Yes 2.5 n.d. High F V 5 AD CAA LBD AS 1.93 Abnormal
90 79 M 332 Yes 2.5 n.d. High F VI 5 AD CAA LBD 2.24 Abnormal
91 80 M 0 Yes 2.6 7.9 High F VI 5 AD 2 Abnormal
92 79 F 422 Yes 2.6 n.d. High F V 5 AD CAA LBD AS VAD HC 2.38 Abnormal
93 87 M 106 Yes 2.6 n.d. High F VI 5 AD 2.2 Abnormal
94 66 F 139 Yes 2.7 n.d. High F VI 5 AD 2.37 Abnormal
95 84 M 181 Yes 2.7 n.d. High F V 4 AD LBD 2.75 Abnormal
96 87 M 769 Yes 2.7 n.d. High F VI 5 AD CAA LBD VAD 2.5 Abnormal
97 71 M 305 Yes 2.7 n.d. High F V 5 AD CAA 2.47 Abnormal
98 72 F 565 Yes 2.7 n.d. High F VI 5 AD CAA LBD 2.58 Abnormal
99 85 M 846 Yes 2.8 n.d. High F VI 5 AD VAD 2.01 Abnormal
100 84 F 198 Yes 2.8 6.3 High F VI 4 AD 1.48 Abnormal
101 85 F 436 Yes 2.9 n.d. High F VI 5 AD 2.65 Abnormal
102 75 F 66 Yes 2.9 10.6 High F VI 5 AD 2.47 Abnormal
103 87 M 493 No 2.9 n.d. High F IV 5 CAA LBD AD 2.42 Abnormal
104 86 F 127 Yes 3.0 n.d. High F VI 5 AD 2.9 Abnormal
105 81 M 171 Yes 3.0 n.d. High F VI 5 AD 2.34 Abnormal
106 63 M 562 Yes 3.0 n.d. High F VI 5 AD 2.72 Abnormal
  1. Subjects are ranked by CERAD neuritic plaque frequency and then by mCERADSOT. AC ageing changes, AD Alzheimer’s disease (high or intermediate likelihood by National Institute of Ageing-Reagan Institute criteria), AS arteriosclerosis or arteriolosclerosis, Ath atherosclerosis, CAA cerebral amyloid angiopathy, FTD frontotemporal lobar degeneration, HC hydrocephalus, Inf infarct, LBD Lewy body disease, mCa metastatic carcinoma, MSA multisystem atrophy, ND neurofibrillary degeneration, PD Parkinson’s disease, PSP progressive supranuclear palsy, SUVR standard retention value ratio, TDP+ TDP43 immunopositivity, TPD tangle-predominant dementia, VSD vascular disease not otherwise specified
  2. aTime between PET imaging and death in days
  3. bDementia recorded in the study medical history
  4. cmCERADSOT; maximal regional mean score determining Standard of Truth assignation as abnormal if > 1.5
  5. dPercentage area of grey matter stained positively by amyloid β immunohistochemistry (4G8) determined only on a subset (32 subjects) of the cohort
  6. eAlzheimer’s Disease likelihood recorded by a neuropathologist against National Institute of Ageing-Reagan Institute criteria [26] but blinded to dementia status
  7. fCERAD neuritic plaque frequency recorded during neuropathology diagnoses (N: none; S: sparse; M: moderate; F: frequent)
  8. gBraak neurofibrillary tangle stage recorded during neuropathology diagnosis
  9. hAmyloid phase [25, 58]
  10. iNeuropathologist’s diagnoses blinded to clinical data. Note: co-incident plaque burden may be present in non-AD diagnoses
  11. jComposite SUVR determined from bilateral measures and normalised to cerebellum as the reference region
  12. kMajority PET image evaluation
  13. lTDP43 immunopositivity was recorded at the site neuropathology laboratories, not as part of the diagnoses for the GE studies. This analysis was not performed on all subjects